Create winning ADC formats which deliver stunning clinical results. Advance your CMC strategy & reduce time to market.

This October, Antibody Drug Conjugate leaders across the globe will convene to share unpublished findings at World ADC San Francisco 2013, the focal point for everyone working on ADCs. That’s over 500 senior ADC scientists and professionals challenging the most advanced scientific thinking.

This year’s overarching theme is translational science. The number of ADCs entering the pipeline is increasing and critical data is now being uncovered enabling better predictions of how these therapies will perform in the clinic and ultimately make it to market.

At World ADC San Francisco, learn from 65 speakers from more than 40 organizations and leave the meeting with all the tools, knowledge and ideas to design and develop the optimal ADC, faster.

Here’s a snap shot of the 60+ speaker line up:

• George Pettit, Regents Professor of Chemistry, Arizona State University
• John Flygare, Senior Scientist, Genentech
• Nitya Ray, Senior Vice President, Manufacturing, Progenics Pharmaceuticals
• Pavel Strop, Associate Research Fellow, Pfizer
• Dimiter Dimitrov, Head, Protein Interaction Group, Senior Investigator, National Cancer Institute
• Omar Kabbarah, Scientist, Oncology Biomarker Development, Genentech
• Jay Harper, Scientist II, Oncology Research, MedImmune
• Karyn O’Neil, CSO, Centyrex, Johnson & Johnson
• Dhaval Shah, Senior Scientist, Pfizer

“World ADC San Francisco was superbly organized and implemented, and a great contribution to the more rapid advances in ADC research, leading to improvements in human cancer treatment. World ADC San is one I am very much looking forward to participating in” Dr Pettit, Arizona State University

Please visit: www.adc-summit.com for more information and to view the agenda.

As always, group discounted rates of up to 20%, as well as early registration discounts are available. Simply visit: www.adc-summit.com or email: info@hansonwade.com for more information.